^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SCRI-CARB7H3(s)

    i
    Company:
    Cellevolve Bio, Seattle Children's Hospital, Seattle Children’s Therapeutics
    Drug class:
    B7-H3-targeted CAR-T immunotherapy
    Related drugs:
    Apply
    B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (STRIvE-02) (NCT04483778)
    Phase 1
    Seattle Children's Hospital
    Active, not recruiting
    Last update posted :
    04/23/2024
    Initiation :
    07/13/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2040
    CD276
    |
    CD276 expression • CD19 expression
    |
    Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1
    Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors (NCT04185038)
    Phase 1
    Seattle Children's Hospital
    Recruiting
    Last update posted :
    12/20/2023
    Initiation :
    12/11/2019
    Primary completion :
    05/01/2026
    Completion :
    05/01/2041
    CD276
    |
    CD276 expression
    |
    SCRI-CARB7H3(s)